Iris Grossman

Iris Grossman is currently a Scientific Advisor at BC Platforms. Prior to that, they were the Chief Scientific Officer at CAMP4 Therapeutics from April 2018 to June 2020. Grossman has also held positions as the VP, Head of Early Stage Clinical Development, global R&D at Teva Pharmaceuticals from May 2013 to March 2018 and as a Strategic Founder Advisor at Modulight.bio. Additionally, they have been a Member of the Board of Advisors at Zinfandel Pharmaceuticals from January 2010 to May 2013.

Iris Grossman has a B.Sc. and Direct PhD from the Technion - Israel Institute of Technology in Medicine / Pharmacogenetics. Iris also has a PhD (collaboration, co-mentors) from the Weizmann Institute of Science in Pharmacogenetics and population genetics. Iris is currently enrolled in the Executive HealthTech Program at Harvard Business School.